Genetic landscape of colorectal cancer patients manifesting tumor shrinkage during SARS-Cov-2 infection.
Alessandro OttaianoMariachiara SantorsolaLuisa CircelliMarco CascellaNadia PetrilloFrancesco PerriMarika CasilloVincenza GranataMonica IannielloFrancesco IzzoCarmine PiconeMarco CorreraAntonella PetrilloRoberto SiricaGabriella MissoPaolo DelrioGuglielmo NastiGiovanni SavareseMichele CaragliaPublished in: Therapeutic advances in medical oncology (2022)
We previously described three patients affected by metastatic colorectal cancer (mCRC) who experienced spontaneous tumour shrinkage during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Thereafter, the patients were closely monitored and no systemic treatments were applied. Here, we report follow-up clinical information about these patients as well as genetic characterization of their primary tumours through the TruSigt™Oncology 500 Next Generation Sequencing test targeting 523 cancer-relevant genes. An Illumina NovaSeq 6000 platform was used to perform sequencing. Time-to-progression was 23 and 2 months, respectively, in Patients 2 and 3 while it was not reached in Patient 1. Patients 1 and 2 had the greatest anti-SARS-CoV-2 IgG titres. Assessment of genetic landscapes evidenced common mutation in BARD1 gene (p.Val507Met) in Patients 1 and 2. Although our report is descriptive in its nature, we suggest that complex and unexplored interactions between genetic background and components of the immune response to SARS-CoV-2 infection could be responsible of unexpected rare mCRC shrinkage.
Keyphrases
- end stage renal disease
- chronic kidney disease
- sars cov
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- healthcare
- respiratory syndrome coronavirus
- squamous cell carcinoma
- genome wide
- gene expression
- young adults
- case report
- palliative care
- single cell
- papillary thyroid
- high throughput
- transcription factor
- lymph node metastasis
- cell free